î
î
Qiagen NV
QGEN50.570USD
-0.500-0.98%
āļāļīāļÂ 07/30, 16:00ïžETïžāļĢāļēāļāļēāļĨāđāļēāļāđāļē 15 āļāļēāļāļĩ
10.95BāļĄāļđāļĨāļāđāļēāļāļĨāļēāļ
116.91P/E TTM
î
āļĢāļēāļĒāļĨāļ°āđāļāļĩāļĒāļāđāļāļīāđāļĄāđāļāļīāļĄāļāļāļ Qiagen NV āļāļĢāļīāļĐāļąāļ
Qiagen NV is a holding company based in the Netherlands. The Company is engaged in providing Sample to Insight solutions that transform biological samples into molecular insights. Its Sample to Insight solutions integrate sample and assay technologies, bioinformatics and automation systems. Its sample technologies are used for isolating and preparing deoxyribonucleic acid (DNA), ribonucleic acid (RNA) and proteins from blood or other liquids, tissue, plants or other materials. Its assay technologies make these biomolecules visible for analysis, such as identifying the genetic information of a pathogen or a gene mutation in a tumor. Its bioinformatics solutions interpret data to provide actionable insights. The Company's automation platforms based on polymerase chain reaction (PCR), next-generation sequencing (NGS) and other technologies tie these together in molecular testing workflows from Sample to Insight.
āļāđāļāļĄāļđāļĨāļāļĢāļīāļĐāļąāļî
āļŠāļąāļāļĨāļąāļāļĐāļāđāļĒāđāļāļāļāļāļŦāļļāđāļQGEN
āļāļ·āđāļāļāļĢāļīāļĐāļąāļQiagen NV
āļ§āļąāļāļāļĩāđāđāļŠāļāļāļāļēāļĒāļāļĢāļąāđāļāđāļĢāļSep 01, 1996
āļāđāļāļāļąāđāļāđāļĄāļ·āđāļ1996
āļāļĩāļāļĩāđāļMr. Thierry Bernard
āļāļģāļāļ§āļāļāļāļąāļāļāļēāļ5765
āļāļĢāļ°āđāļ āļāļāļēāļĢāļĢāļąāļāļĐāļēāļāļ§āļēāļĄāļāļĨāļāļāļ āļąāļĒOrdinary Share
āļŠāļīāđāļāļāļĩāļāļāļāļĢāļ°āļĄāļēāļSep 01
āļāļĩāđāļāļĒāļđāđHulsterweg 82
āđāļĄāļ·āļāļVENLO
āļāļĨāļēāļāļŦāļĨāļąāļāļāļĢāļąāļāļĒāđNYSE Consolidated
āļāļĢāļ°āđāļāļĻNetherlands
āļĢāļŦāļąāļŠāđāļāļĢāļĐāļāļĩāļĒāđ5912 PL
āđāļāļĢāļĻāļąāļāļāđ31773556600
āđāļ§āđāļāđāļāļāđhttps://www.qiagen.com/
āļŠāļąāļāļĨāļąāļāļĐāļāđāļĒāđāļāļāļāļāļŦāļļāđāļQGEN
āļ§āļąāļāļāļĩāđāđāļŠāļāļāļāļēāļĒāļāļĢāļąāđāļāđāļĢāļSep 01, 1996
āļāđāļāļāļąāđāļāđāļĄāļ·āđāļ1996
āļāļđāđāļāļĢāļīāļŦāļēāļĢāļāļĢāļīāļĐāļąāļî
āļāļ·āđāļ
āļāļ·āđāļ/āļāļģāđāļŦāļāđāļ
āļāļģāđāļŦāļāđāļ
āļāļēāļĢāļāļ·āļāļŦāļļāđāļ
āđāļāļĨāļĩāđāļĒāļ
Mr. Roland Sackers
Mr. Roland Sackers
Managing Director, Chief Financial Officer, Member of the Executive Board
Managing Director, Chief Financial Officer, Member of the Executive Board
383.09K
+59.93%
Mr. Thierry Bernard
Mr. Thierry Bernard
Chief Executive Officer, Managing Director, Member of the Executive Board
Chief Executive Officer, Managing Director, Member of the Executive Board
312.13K
+75.76%
Dr. Metin Colpan, Ph.D.
Dr. Metin Colpan, Ph.D.
Independent Member of the Supervisory Board
Independent Member of the Supervisory Board
171.79K
-57.00%
Tallett (Elizabeth E)
Tallett (Elizabeth E)
Independent Member of the Supervisory Board
Independent Member of the Supervisory Board
47.22K
+10.37%
Prof. Dr. Ross L. Levine, M.D.
Prof. Dr. Ross L. Levine, M.D.
Independent Member of the Supervisory Board
Independent Member of the Supervisory Board
16.27K
+30.83%
Prof. Dr. Elaine R. Mardis, Ph.D.
Prof. Dr. Elaine R. Mardis, Ph.D.
Independent Member of the Supervisory Board
Independent Member of the Supervisory Board
3.97K
--
Mr. Stephen H. (Steve) Rusckowski
Mr. Stephen H. (Steve) Rusckowski
Independent Chairman of the Supervisory Board
Independent Chairman of the Supervisory Board
24.00
--
Ms. Eva van Pelt
Ms. Eva van Pelt
Independent Member of the Supervisory Board
Independent Member of the Supervisory Board
--
--
Dr. Toralf Haag, Ph.D.
Dr. Toralf Haag, Ph.D.
Independent Member of the Supervisory Board
Independent Member of the Supervisory Board
--
--
Mr. Bert van Meurs
Mr. Bert van Meurs
Independent Member of the Supervisory Board
Independent Member of the Supervisory Board
--
--
āļāļđāđāļāļīāđāļĄāđāļāļīāļĄ
āļāļ·āđāļ
āļāļ·āđāļ/āļāļģāđāļŦāļāđāļ
āļāļģāđāļŦāļāđāļ
āļāļēāļĢāļāļ·āļāļŦāļļāđāļ
āđāļāļĨāļĩāđāļĒāļ
Mr. Roland Sackers
Mr. Roland Sackers
Managing Director, Chief Financial Officer, Member of the Executive Board
Managing Director, Chief Financial Officer, Member of the Executive Board
383.09K
+59.93%
Mr. Thierry Bernard
Mr. Thierry Bernard
Chief Executive Officer, Managing Director, Member of the Executive Board
Chief Executive Officer, Managing Director, Member of the Executive Board
312.13K
+75.76%
Dr. Metin Colpan, Ph.D.
Dr. Metin Colpan, Ph.D.
Independent Member of the Supervisory Board
Independent Member of the Supervisory Board
171.79K
-57.00%
Tallett (Elizabeth E)
Tallett (Elizabeth E)
Independent Member of the Supervisory Board
Independent Member of the Supervisory Board
47.22K
+10.37%
Prof. Dr. Ross L. Levine, M.D.
Prof. Dr. Ross L. Levine, M.D.
Independent Member of the Supervisory Board
Independent Member of the Supervisory Board
16.27K
+30.83%
Prof. Dr. Elaine R. Mardis, Ph.D.
Prof. Dr. Elaine R. Mardis, Ph.D.
Independent Member of the Supervisory Board
Independent Member of the Supervisory Board
3.97K
--
āļŠāļąāļāļŠāđāļ§āļāļāļāļāļĢāļēāļĒāđāļāđ
āļŠāļāļļāļĨāđāļāļīāļ: USDāļāļąāļāđāļāļāđāļĄāļ·āđāļ: āļ§āļąāļāļāļēāļāļīāļāļĒāđāļāļĩāđ 6 āļ.āļ.
āļŠāļāļļāļĨāđāļāļīāļ: USDāļāļąāļāđāļāļāđāļĄāļ·āđāļ: āļ§āļąāļāļāļēāļāļīāļāļĒāđāļāļĩāđ 6 āļ.āļ.
FY2025Q1
FY2024
FY2024Q4
FY2024Q3
FY2024Q2
FY2024Q1
FY2023
FY2023Q4
FY2023Q3
FY2023Q2
FY2023Q1
FY2022
FY2022Q4
FY2022Q3
FY2022Q2
FY2022Q1
FY2021
FY2020
FY2019
FY2018
FY2017
FY2016
FY2015
āļāļēāļĄāļāļļāļĢāļāļīāļUSD
āļāļ·āđāļ
āļĢāļēāļĒāđāļāđ
āļŠāļąāļāļŠāđāļ§āļ
Consumables and Related Revenues
435.06M
89.99%
Instrumentation
48.39M
10.01%
āļāļēāļĄāļ āļđāļĄāļīāļ āļēāļUSD
āļāļ·āđāļ
āļĢāļēāļĒāđāļāđ
āļŠāļąāļāļŠāđāļ§āļ
United States
232.85M
48.16%
Europe & Middle East & Africa
160.64M
33.23%
Asia, Pacific & Rest of the World
68.83M
14.24%
Other Americas
21.13M
4.37%
āļāļēāļĄāļāļļāļĢāļāļīāļ
āļāļēāļĄāļ āļđāļĄāļīāļ āļēāļ
āļāļēāļĄāļāļļāļĢāļāļīāļUSD
āļāļ·āđāļ
āļĢāļēāļĒāđāļāđ
āļŠāļąāļāļŠāđāļ§āļ
Consumables and Related Revenues
435.06M
89.99%
Instrumentation
48.39M
10.01%
āļŠāļāļīāļāļīāļāļēāļĢāļāļ·āļāļŦāļļāđāļ
āļāļąāļāđāļāļāđāļĄāļ·āđāļ: āļ§āļąāļāđāļŠāļēāļĢāđāļāļĩāđ 14 āļĄāļī.āļĒ.
āļāļąāļāđāļāļāđāļĄāļ·āđāļ: āļ§āļąāļāđāļŠāļēāļĢāđāļāļĩāđ 14 āļĄāļī.āļĒ.
āļāļđāđāļāļ·āļāļŦāļļāđāļ
āļāļĢāļ°āđāļ āļāļāļđāđāļāļ·āļāļŦāļļāđāļ
āļāļđāđāļāļ·āļāļŦāļļāđāļ
āļāļđāđāļāļ·āļāļŦāļļāđāļ
āļŠāļąāļāļŠāđāļ§āļ
Wellington Management Company, LLP
11.29%
MFS Investment Management
11.20%
BlackRock Institutional Trust Company, N.A.
9.36%
The Vanguard Group, Inc.
4.06%
Amundi Asset Management, SAS
1.94%
Other
62.16%
āļāļđāđāļāļ·āļāļŦāļļāđāļ
āļāļđāđāļāļ·āļāļŦāļļāđāļ
āļŠāļąāļāļŠāđāļ§āļ
Wellington Management Company, LLP
11.29%
MFS Investment Management
11.20%
BlackRock Institutional Trust Company, N.A.
9.36%
The Vanguard Group, Inc.
4.06%
Amundi Asset Management, SAS
1.94%
Other
62.16%
āļāļĢāļ°āđāļ āļāļāļđāđāļāļ·āļāļŦāļļāđāļ
āļāļđāđāļāļ·āļāļŦāļļāđāļ
āļŠāļąāļāļŠāđāļ§āļ
Investment Advisor/Hedge Fund
42.33%
Investment Advisor
33.64%
Hedge Fund
3.23%
Research Firm
3.22%
Sovereign Wealth Fund
1.87%
Pension Fund
1.59%
Holding Company
1.17%
Bank and Trust
1.06%
Individual Investor
0.44%
Other
11.44%
āļāļēāļĢāļāļ·āļāļŦāļļāđāļāļāļāļāļŠāļāļēāļāļąāļî
āļāļąāļāđāļāļāđāļĄāļ·āđāļ: āļ§āļąāļāļāļąāļāļāļēāļĢāļāļĩāđ 1 āļ.āļ.
āļāļąāļāđāļāļāđāļĄāļ·āđāļ: āļ§āļąāļāļāļąāļāļāļēāļĢāļāļĩāđ 1 āļ.āļ.
āļāđāļ§āļāđāļ§āļĨāļēāļāļēāļĢāļĢāļēāļĒāļāļēāļ
āļāļģāļāļ§āļāļŠāļāļēāļāļąāļ
āļŦāļļāđāļāļāļĩāđāļāļ·āļāļāļĢāļāļ
āļŠāļąāļāļŠāđāļ§āļ
āđāļāļĨāļĩāđāļĒāļ
2025Q2
974
192.24M
88.77%
+36.58M
2025Q1
1017
179.03M
82.67%
+27.58M
2024Q4
1010
129.03M
59.70%
-70.06M
2024Q3
1010
183.22M
84.72%
-23.62M
2024Q2
1002
184.34M
84.75%
+8.40M
2024Q1
988
165.20M
76.61%
-7.18M
2023Q4
993
165.11M
76.72%
-10.52M
2023Q3
987
159.93M
74.32%
-12.21M
2023Q2
996
162.43M
75.49%
-6.05M
2023Q1
1001
160.07M
74.44%
-9.45M
āļāļđāđāļāļīāđāļĄāđāļāļīāļĄ
āļāļīāļāļāļĢāļĢāļĄāļāļđāđāļāļ·āļāļŦāļļāđāļî
āļāļ·āđāļ
āļŦāļļāđāļāļāļĩāđāļāļ·āļāļāļĢāļāļ
āļŠāļąāļāļŠāđāļ§āļ
āđāļāļĨāļĩāđāļĒāļ
āđāļāļĨāļĩāđāļĒāļ%
āļ§āļąāļāļāļĩāđ
Wellington Management Company, LLP
24.44M
11.29%
+1.15M
+4.92%
Mar 31, 2025
MFS Investment Management
24.26M
11.2%
+24.26M
--
Mar 31, 2025
BlackRock Institutional Trust Company, N.A.
20.17M
9.31%
-350.47K
-1.71%
Jun 16, 2025
The Vanguard Group, Inc.
8.78M
4.06%
+245.16K
+2.87%
Mar 31, 2025
Amundi Asset Management, SAS
4.19M
1.94%
-516.05K
-10.96%
Mar 31, 2025
T. Rowe Price International Ltd
4.15M
1.92%
+4.01M
+2888.12%
Mar 31, 2025
Norges Bank Investment Management (NBIM)
3.96M
1.83%
-111.67K
-2.74%
Dec 31, 2024
EARNEST Partners, LLC
3.81M
1.76%
+3.81M
--
Mar 31, 2025
DWS Investments UK Limited
3.43M
1.58%
+1.29M
+60.58%
Mar 31, 2025
Swedbank Robur Fonder AB
3.06M
1.41%
+186.76K
+6.51%
May 31, 2025
āļāļđāđāļāļīāđāļĄāđāļāļīāļĄ
ETF āļāļĩāđāđāļāļĩāđāļĒāļ§āļāđāļāļî
āļāļąāļāđāļāļāđāļĄāļ·āđāļ: āļ§āļąāļāļāļēāļāļīāļāļĒāđāļāļĩāđ 6 āļ.āļ.
āļāļąāļāđāļāļāđāļĄāļ·āđāļ: āļ§āļąāļāļāļēāļāļīāļāļĒāđāļāļĩāđ 6 āļ.āļ.
āļāļ·āđāļ
āļŠāļąāļāļŠāđāļ§āļ
First Trust Nasdaq Lux Digi Health Solutions ETF
4.59%
Global X Genomics & Biotechnology ETF
4.55%
Invesco Biotechnology & Genome ETF
3.3%
Franklin Genomic Advancements ETF
1.87%
VanEck Biotech ETF
1.85%
ROBO Global Healthcare Technology & Innovation ETF
1.82%
Pacer US Large Cap Cash Cows Growth Leaders ETF
1.21%
iShares Health Innovation Active ETF
1.02%
Harbor Long-Short Equity ETF
0.9%
FlexShares US Quality Low Volatility Index Fund
0.85%
āļāļđāđāļāļīāđāļĄāđāļāļīāļĄ
First Trust Nasdaq Lux Digi Health Solutions ETF
āļŠāļąāļāļŠāđāļ§āļ4.59%
Global X Genomics & Biotechnology ETF
āļŠāļąāļāļŠāđāļ§āļ4.55%
Invesco Biotechnology & Genome ETF
āļŠāļąāļāļŠāđāļ§āļ3.3%
Franklin Genomic Advancements ETF
āļŠāļąāļāļŠāđāļ§āļ1.87%
VanEck Biotech ETF
āļŠāļąāļāļŠāđāļ§āļ1.85%
ROBO Global Healthcare Technology & Innovation ETF
āļŠāļąāļāļŠāđāļ§āļ1.82%
Pacer US Large Cap Cash Cows Growth Leaders ETF
āļŠāļąāļāļŠāđāļ§āļ1.21%
iShares Health Innovation Active ETF
āļŠāļąāļāļŠāđāļ§āļ1.02%
Harbor Long-Short Equity ETF
āļŠāļąāļāļŠāđāļ§āļ0.9%
FlexShares US Quality Low Volatility Index Fund
āļŠāļąāļāļŠāđāļ§āļ0.85%
āđāļāļīāļāļāļąāļāļāļĨî
āļĄāļĩāļāļēāļĢāļāđāļēāļĒāđāļāļīāļāļāļąāļāļāļĨāđāļāđāļāļāļģāļāļ§āļāļĢāļ§āļĄ
0.00
USD āđāļāļāđāļ§āļ 5 āļāļĩāļāļĩāđāļāđāļēāļāļĄāļē
āļ§āļąāļāļāļĩāđ
āđāļāļīāļāļāļąāļāļāļĨ
āļ§āļąāļāļāļĩāđāļāļąāļāļāļķāļ
āļ§āļąāļāļāļĩāđāļāļģāļĢāļ°āđāļāļīāļ
āļ§āļąāļāļāļĩāđāđāļĄāđāđāļāđāļĢāļąāļāļŠāļīāļāļāļīāļāļąāļāļāļĨ
āđāļĄāđāļĄāļĩāļāđāļāļĄāļđāļĨ
āļāļēāļĢāđāļāđāļāļŦāļļāđāļî
āļ§āļąāļāļāļĩāđ
āļāļĢāļ°āđāļ āļ
āļāļąāļāļĢāļēāļŠāđāļ§āļ
Jan 17, 2025
Merger
36<35
Jan 17, 2025
Merger
36<35
Jan 17, 2025
Merger
36<35
Jan 17, 2025
Merger
36<35
Jan 18, 2024
Merger
25<24.25
Jan 18, 2024
Merger
25<24.25
āļ§āļąāļāļāļĩāđ
āļāļĢāļ°āđāļ āļ
āļāļąāļāļĢāļēāļŠāđāļ§āļ
Jan 17, 2025
Merger
36<35
Jan 17, 2025
Merger
36<35
Jan 17, 2025
Merger
36<35
Jan 17, 2025
Merger
36<35
Jan 18, 2024
Merger
25<24.25
Jan 18, 2024
Merger
25<24.25
Jan 18, 2024
Merger
25<24.25
Jan 18, 2024
Merger
25<24.25
